8-KMaterial AgreementsFinancial EventsExhibits & Filings

HCA Healthcare, Inc. 8-K Report, Material Agreement (Apr 8, 2010)

Filed April 8, 2010For Securities:HCA

Summary

This 8-K filing from HCA Healthcare, Inc. (HCA) on April 7, 2010, reports on a significant amendment to its existing Credit Agreement, dated November 17, 2006. The primary focus is the "Extension Amendment No. 1," which, among other provisions, extends the maturity date for $2.0 billion of the Company's tranche B term loans to March 31, 2017. This extension provides HCA with greater financial flexibility and a longer runway for a substantial portion of its debt. Additionally, the amendment adjusts the interest margins for these extended loans, increasing the ABR margin to 2.25% and the LIBOR margin to 3.25%. While this represents an increase in borrowing costs for this specific tranche of debt, it is likely a consequence of securing a longer maturity period. Importantly, all other loans, commitments, and letters of credit under the Credit Agreement remain unaffected by this amendment.

Key Highlights

  • 1HCA Healthcare entered into Extension Amendment No. 1 to its Credit Agreement on April 6, 2010.
  • 2The amendment extends the maturity date of $2.0 billion of tranche B term loans to March 31, 2017.
  • 3This extension provides a longer-term financing solution for a significant portion of HCA's debt.
  • 4The ABR margin for the extended term loans increased to 2.25%.
  • 5The LIBOR margin for the extended term loans increased to 3.25%.
  • 6Maturity dates, margins, and commitments for other outstanding loans remain unchanged.
  • 7The amendment was entered into by HCA Inc., its European Subsidiary Borrower, guarantors, lenders, and Bank of America, N.A. as administrative agent.

Frequently Asked Questions

The main purpose of the Extension Amendment is to extend the maturity date of $2.0 billion of HCA's tranche B term loans from the original maturity to March 31, 2017. This effectively provides the company with an additional seven years for this portion of its debt.

The amendment increases the interest margins for the extended term loans. The ABR margin is now 2.25% and the LIBOR margin is 3.25%. This means that the interest paid on this $2.0 billion tranche of debt will be higher compared to the previous terms.

No, only the specified $2.0 billion of tranche B term loans are affected by the maturity extension and margin changes. All other loans, commitments, and letters of credit outstanding under the Credit Agreement remain unchanged by this particular amendment.

Extending debt maturity is generally viewed positively by investors as it reduces the company's immediate refinancing risk and provides greater financial flexibility. It allows the company to manage its cash flow over a longer period without the pressure of repaying a large sum in the near term, potentially enabling better strategic planning and execution.